National Key Laboratory of Medical Chemical Biology & Tianjin Key Laboratory of Protein Science, Nankai University, Tianjin, 300071, China.
Biotherapy Center, People's Liberation Army No. 254 Hospital, Tianjin, 300142, China.
Biomaterials. 2017 Jul;134:51-63. doi: 10.1016/j.biomaterials.2017.04.035. Epub 2017 Apr 22.
New strategies with the ability to enhance both the humoral and cellular immune responses remain a priority for the development of future therapeutic cancer vaccines. In this study, we took advantage of β-glucan particles (GPs) derived from Saccharomyces cerevisiae baker's yeast and a novel reverse micro-emulsion method to prepare an antigen-loaded GP carrier system for dendritic cell (DC) specific antigen delivery, followed by careful evaluation of the immune functions of the prepared particles in initiating both the humoral and cellular immune responses through in vitro and in vivo experiments. The prepared particles greatly promoted DC activation and cytokine production and cross presented the antigen to CD8 cells, inducing very strong OVA specific humoral and cellular immune responses. Treatment with these particles significantly prevented the growth of implanted EG7-OVA tumors in a prophylactic and pre-established tumor model. These results suggest that our strategy may be able to be utilized as a promising platform for cancer immunotherapy.
新的策略,能够增强体液和细胞免疫反应,仍然是未来治疗性癌症疫苗发展的重点。在这项研究中,我们利用β-葡聚糖颗粒(GPs)从酿酒酵母酵母和一种新的反向微乳液方法来制备负载抗原的 GP 载体系统树突状细胞(DC)特异性抗原传递,然后仔细评估通过体外和体内实验制备颗粒在启动体液和细胞免疫反应中的免疫功能。所制备的颗粒极大地促进了 DC 的激活和细胞因子的产生,并将抗原交叉呈递给 CD8 细胞,诱导非常强烈的 OVA 特异性体液和细胞免疫反应。用这些颗粒治疗可显著预防植入的 EG7-OVA 肿瘤在预防性和预先建立的肿瘤模型中的生长。这些结果表明,我们的策略可能能够被用作癌症免疫治疗的一个有前途的平台。